Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates

Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Is a Surprise Coming for Illumina (ILMN) This Earnings Season?

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Daniel Laboe headshot

The Markets' Tone: Cautiously Optimistic

As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds

Illumina (ILMN) to Address Nasopharynx Cancer With New Pact

Illumina's (ILMN) recent collaboration will fuel initiatives that enhance health outcomes for people living with nasopharynx cancer and advance the development of personalized treatment.

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Here's Why You Should Hold on to Illumina (ILMN) for Now

Investors are optimistic about Illumina (ILMN) owing to its strength in international markets and notable strategic partnerships.

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Company News for Jan 12, 2022

Companies in The News Are: ACCD,PACB,BIG,ILMN

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View

Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.

Rimmi Singhi headshot

4 Toxic Stocks to Eliminate From Your Portfolio Now

Detecting toxic stocks and dumping them at the right time is crucial to avoid big losses. ILMN, TCMD, CTOS and GCI are a few toxic stocks that don't deserve a place in your portfolio.

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Mark Vickery headshot

Remedies for Omicron Apparent, Markets Up Again

New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.

Rimmi Singhi headshot

Don't Squander Your Income on These 3 Toxic Stocks

Precisely figuring out toxic stocks and discarding or short selling those at the right time is the key to safeguarding your portfolio from big losses.

Illumina's (ILMN) New Alliance to Accelerate Genomics in China

Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.

Illumina (ILMN) iHope Genetic Health Program Expands WGS Access

Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up

Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.

Illumina (ILMN) Surpasses Q3 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of 16.94% and 6.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

EXEL vs. ILMN: Which Stock Is the Better Value Option?

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Daniel Laboe headshot

Will Christmas Come Early For Investors This Year?

Welcome to November, the seasonally strongest month for S&P 500 returns, averaging growth of 2.5% over the past decade